Rapid Micro Biosystems Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
26.3%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$39.3Mnext fiscal year
FY EPS (est.)
-$0.93next fiscal year
Monitoring Framework
Key Performance Indicators
Growth Direct System Placements Quarterly600.0%Target: 30 to 38 placements
System Validations Completed Quarterly5.0Target: At least 25 validations
Recurring Revenue Quarterly5.1M
Gross Margin Percentage Quarterly460.0%Target: Approximately 20%
Watch Items
- Gross Margin RecoveryTrigger: Gross margin falling below 15% in Q2 2026 or failing to reach mid-20% exit rate by Q4 2026Action: Re-evaluate manufacturing scale, pricing power, and cost-reduction initiatives for consumables and systems.
- System Placement CadenceTrigger: Cumulative placements tracking below the lower bound of the 30 to 38 full-year guidance rangeAction: Assess sales pipeline conversion rates, regional performance (US vs. Europe/Asia), and customer capital expenditure constraints.
Research as of 20 Jun 2026